Growth Differentiation Factor-15 Is a Novel Biomarker Predicting Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Inflammation

Volumn 38, Issue 5, 2015, Pages 1805-1813

  Mutlu, Levent Cem ^a   Altintas, Nejat ^a   Aydin, Murat ^a   Tulubas, Feti ^a   Oran, Mustafa ^a   Kucukyalin, Volkan ^a   Kaplan, Gizem ^a   Gurel, Ahmet ^a  

^a NAMIK KEMAL UNIVERSITY   (Turkey)

Author keywords

biomarker; chronic obstructive pulmonary disease; growth differentiation factor 15; inflammation

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; GROWTH DIFFERENTIATION FACTOR 15; GDF15 PROTEIN, HUMAN;

AGED; ARTERIAL GAS; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE EXACERBATION; FEMALE; HUMAN; LUNG FUNCTION TEST; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATHOGENESIS; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; ACUTE DISEASE; BLOOD; CROSS-SECTIONAL STUDY; DISEASE COURSE; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX;

ACUTE DISEASE; AGED; BIOMARKERS; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX;

EID: 84941167434     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-015-0158-5     Document Type: Article

References (34)

1. Decramer, M., W. Janssens, and M. Miravitlles. 2012. Chronic obstructive pulmonary disease. Lancet 379: 1341–1351.
2. Miravitlles, M., and A. Anzueto. 2014. Antibiotic prophylaxis in COPD: why, when, and for whom? Pulmonary Pharmacology and Therapeutics
3. Doll, H., and M. Miravitlles. 2005. Health-related QOL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature. PharmacoEconomics 23: 345–363.
4. Soler-Cataluña, J.J., M.A. Martinez-Garcia, P. Román Sánchez, E. Salcedo, M. Navarro, and R. Ochando. 2005. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60: 925–931.
5. Rodriguez-Roisin, R. 2000. Toward a consensus definition for COPD exacerbations. Chest 117: 398S–401S.
6. Hurst, J.R., G.C. Donaldson, W.R. Perera, T.M.A. Wilkinson, J.A. Bilello, G.W. Hagan, R.S. Vessey, and J.A. Wedzicha. 2006. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 174: 867–874.
7. Donaldson, G.C., T.A. R. Seemungal, I.S. Patel, A. Bhowmik, T.M.A. Wilkinson, J.R. Hurst, P.K. MacCallum, and J.A. Wedzicha. 2009. Airway and systemic inflammation and decline in lung function in patients with COPD. 2005. Chest. Vol. 136.
8. Vestbo, J., S.S. Hurd, A.G. Agustí, P.W. Jones, C. Vogelmeier, A. Anzueto, P.J. Barnes, et al. 2013. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. American Journal of Respiratory and Critical Care Medicine 187: 347–365.
9. Bootcov, M.R., A.R. Bauskin, S.M. Valenzuela, A.G. Moore, M. Bansal, X.Y. He, H.P. Zhang, et al. 1997. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proceedings of the National Academy of Sciences of the United States of America 94: 11514–11519.
10. Kempf, T., S. von Haehling, T. Peter, T. Allhoff, M. Cicoira, W. Doehner, P. Ponikowski, et al. 2007. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. Journal of the American College of Cardiology 50: 1054–1060.
11. Foley, P.W.X., B. Stegemann, K. Ng, S. Ramachandran, A. Proudler, M.P. Frenneaux, L.L. Ng, and F. Leyva. 2009. Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy. European Heart Journal 30: 2749–2757.
12. Richter, B., L. Koller, P.J. Hohensinner, G. Zorn, M. Brekalo, R. Berger, D. Mörtl, et al. 2013. A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure. International Journal of Cardiology 168: 1251–1257.
13. Eitel, I., P. Blase, V. Adams, L. Hildebrand, S. Desch, G. Schuler, and H. Thiele. 2011. Growth-differentiation factor 15 as predictor of mortality in acute reperfused ST-elevation myocardial infarction: insights from cardiovascular magnetic resonance. Heart (British Cardiac Society) 97: 632–640.
14. Widera, C., M.J. Pencina, A. Meisner, T. Kempf, K. Bethmann, I. Marquardt, H.A. Katus, E. Giannitsis, and K.C. Wollert. 2012. Adjustment of the GRACE score by growth differentiation factor 15 enables a more accurate appreciation of risk in non-ST-elevation acute coronary syndrome. European Heart Journal 33: 1095–1104.
15. Lankeit, M., T. Kempf, C. Dellas, M. Cuny, H. Tapken, T. Peter, M. Olschewski, S. Konstantinides, and K.C. Wollert. 2008. Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism. American Journal of Respiratory and Critical Care Medicine 177: 1018–1025.
16. Lambrecht, S., V. Smith, K. De Wilde, J. Coudenys, S. Decuman, D. Deforce, F. De Keyser, and D. Elewaut. 2014. Growth differentiation factor 15, a marker of lung involvement in systemic sclerosis, is involved in fibrosis development but is not indispensable for fibrosis development. Arthritis & Rheumatology 66: 418–427.
17. Bozinovski, S., A. Hutchinson, M. Thompson, L. Macgregor, J. Black, E. Giannakis, A.-S. Karlsson, et al. 2008. Serum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 177: 269–278.
18. Wallentin, L., B. Zethelius, L. Berglund, K.M. Eggers, L. Lind, B. Lindahl, K.C. Wollert, and A. Siegbahn. 2013. GDF-15 for prognostication of cardiovascular and cancer morbidity and mortality in men. PLoS ONE 8: e78797.
19. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of COPD: updated 2014. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014_Jun11.pdf (accessed July 30, 2014).
20. Celli, B.R., W. MacNee, and ATS/ERS Task Force. 2004. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. European Respiratory Journal 23: 932–946.
21. Halpin, D.M.G., M. Decramer, B. Celli, S. Kesten, D. Liu, and D.P. Tashkin. 2012. Exacerbation frequency and course of COPD. International Journal of Chronic Obstructive Pulmonary Disease 7: 653–661.
22. Tufvesson, E., M. Ekberg, and L. Bjermer. 2013. Inflammatory biomarkers in sputum predict COPD exacerbations. Lung 191: 413–416.
23. Miniati, M., S. Monti, M. Bottai, F. Cocci, E. Fornai, and V. Lubrano. 2011. Prognostic value of C-reactive protein in chronic obstructive pulmonary disease. Internal and Emergency Medicine 6: 423–430.
24. Thomsen, M., M. Dahl, P. Lange, J. Vestbo, and B.G. Nordestgaard. 2012. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 186: 982–988.
25. Moberg, M., J. Vestbo, G. Martinez, P. Lange, and T. Ringbaek. 2014. Prognostic value of C-reactive protein, leukocytes, and vitamin D in severe chronic obstructive pulmonary disease. ScientificWorldJournal 2014: 140736.
26. De Torres, J.P., V. Pinto-Plata, C. Casanova, H. Mullerova, E. Córdoba-Lanús, M. Muros de Fuentes, A. Aguirre-Jaime, and B.R. Celli. 2008. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 133: 1336–1343.
27. Thomsen, M., T.S. Ingebrigtsen, J.L. Marott, M. Dahl, P. Lange, J. Vestbo, and B.G. Nordestgaard. 2013. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA 309: 2353–2361.
28. Lindahl, B. 2013. The story of growth differentiation factor 15: another piece of the puzzle. Clinical Chemistry 59: 1550–1552.
29. Griner, S.E., J.P. Joshi, and R. Nahta. 2013. Growth differentiation factor 15 stimulates rapamycin-sensitive ovarian cancer cell growth and invasion. Biochemical Pharmacology 85: 46–58.
30. Dickens, J.A., B.E. Miller, L.D. Edwards, E.K. Silverman, D.A. Lomas, R. Tal- Singer, and Evaluation of COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE) study investigators. 2011. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respiratory Research 12: 146.
31. Daniels, L.B., P. Clopton, G.A. Laughlin, A.S. Maisel, and E.B. Connor. 2011. Growth-differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: the Rancho Bernardo Study. Circulation 123: 2101–2110.
32. Rodriguez, A.D., P.A. Gonzalez, and P. Avanzas. 2014. Usefulness of growth differentiation factor-15 levels to predict diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes mellitus. American Journal of Cardiology 114: 890–894.
33. Finkenstedt, A., A. Widschwendter, C.G. Brasse-Lagnel, I. Theurl, M. Hubalek, H. Dieplinger, C. Tselepis, D.G. Ward, W. Vogel, and H. Zoller. 2012. Hepcidin is correlated to soluble hemojuvelin but not to increased GDF15 during pregnancy. Blood Cells, Molecules & Diseases 48: 233–237.
34. Trovik, J., H.B. Salvesen, T. Cuppens, F. Amant, and A.C. Staff. 2014. Growth differentiation factor-15 as biomarker in uterine sarcomas. International Journal of Gynecological Cancer 24: 252–259.